Jones Financial Companies Lllp Has $118,000 Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Jones Financial Companies Lllp grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 16.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 641 shares of the medical research company’s stock after buying an additional 90 shares during the period. Jones Financial Companies Lllp’s holdings in Charles River Laboratories International were worth $118,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in Charles River Laboratories International in the 3rd quarter worth $601,000. JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after purchasing an additional 85,759 shares during the period. State Street Corp lifted its position in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Charles River Laboratories International by 3.4% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock worth $22,060,000 after buying an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after buying an additional 3,268 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling

In other news, COO Birgit Girshick purchased 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Trading Up 2.6 %

Shares of CRL stock opened at $171.27 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company has a 50-day simple moving average of $167.74 and a two-hundred day simple moving average of $184.59. The company has a market capitalization of $8.76 billion, a price-to-earnings ratio of 1,141.78, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.46 earnings per share. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on CRL shares. Barclays dropped their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, The Goldman Sachs Group dropped their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).